Performance of common imaging techniques vs serum biomarkers in assessing fibrosis in patients with chronic hepatitis B: A systematic review and meta-analysis

Table 3 Subgroup analysis of prevalence of F2 in prediction of significant fibrosis

Diagnostic test	F2%	Number of studies (n)	AUSROC (95%CI)	SEN (95%CI)	SPE (95%CI)
APRI	F2% < 50	16 (4566)	0.72 (0.68-0.76)	0.68 (0.59-0.76)	0.66 (0.57-0.75)
	F2% ≥ 50	31 (9159)	0.77 (0.73-0.81)	0.69 (0.62-0.75)	0.73 (0.68-0.78)
FIB-4	F2% < 50	9 (3234)	0.75 (0.71-0.79)	0.60 (0.47-0.72)	0.76 (0.68-0.83)
	F2% ≥ 50	23 (7945)	0.75 (0.71-0.78)	0.63 (0.57-0.68)	0.74 (0.69-0.78)
ARFI	F2% < 50	4 (554)	0.89 (0.85-0.91)	0.73 (0.62-0.82)	0.93 (0.68-0.97)
	F2% ≥ 50	7 (973)	0.88 (0.85-0.91)	0.80 (0.72-0.87)	0.82 (0.74-0.88)
Fibroscan	F2% < 50	12 (2272)	0.85 (0.81-0.88)	0.77 (0.70-0.83)	0.80 (0.71-0.86)
	F2% ≥ 50	17 (2763)	0.82 (0.78-0.85)	0.69 (0.64-0.74)	0.84 (0.78-0.88)

SEN: Sensitivity; SPE: Specificity; CI: Confidence interval; AUSROC: The area under the summary receiver operating characteristic curve; APRI: Aminotransferase-to-platelet ratio index; FIB-4: Fibrosis index based on the 4 factors; ARFI: Acoustic radiation force impulse.